Gilead Sciences PE Ratio 2006-2021 | GILD

Current and historical p/e ratio for Gilead Sciences (GILD) from 2006 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Gilead Sciences PE ratio as of January 21, 2022 is 7.71.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Gilead Sciences PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-01-21 68.51 11.69
2021-09-30 69.15 $5.86 11.80
2021-06-30 67.49 $4.10 16.46
2021-03-31 62.69 $0.23 272.58
2020-12-31 55.87 $0.08 698.38
2020-09-30 59.92 $0.97 61.77
2020-06-30 72.22 $-0.24 0.00
2020-03-31 69.52 $3.89 17.87
2019-12-31 59.83 $4.21 14.21
2019-09-30 57.82 $2.09 27.67
2019-06-30 61.05 $4.61 13.24
2019-03-31 58.20 $4.53 12.85
2018-12-31 55.46 $4.16 13.33
2018-09-30 67.88 $1.20 56.57
2018-06-30 61.81 $1.66 37.23
2018-03-31 65.26 $2.60 25.10
2017-12-31 61.57 $3.48 17.69
2017-09-30 69.15 $8.78 7.88
2017-06-30 60.03 $9.21 6.52
2017-03-31 57.14 $9.46 6.04
2016-12-31 59.79 $9.94 6.02
2016-09-30 65.65 $10.78 6.09
2016-06-30 68.80 $11.35 6.06
2016-03-31 75.34 $11.69 6.44
2015-12-31 82.60 $11.92 6.93
2015-09-30 79.60 $10.92 7.29
2015-06-30 94.79 $9.53 9.95
2015-03-31 79.16 $8.81 8.98
2014-12-31 76.03 $7.38 10.30
2014-09-30 85.87 $5.67 15.14
2014-06-30 66.88 $4.47 14.96
2014-03-31 57.16 $2.73 20.94
2013-12-31 60.58 $1.83 33.10
2013-09-30 50.71 $1.83 27.71
2013-06-30 41.36 $1.79 23.17
2013-03-31 39.48 $1.79 22.12
2012-12-31 29.62 $1.65 18.01
2012-09-30 26.75 $1.61 16.62
2012-06-30 20.68 $1.66 12.46
2012-03-31 19.71 $1.67 11.84
2011-12-31 16.51 $1.78 9.30
2011-09-30 15.65 $1.72 9.10
2011-06-30 16.70 $1.66 10.06
2011-03-31 17.13 $1.59 10.77
2010-12-31 14.62 $1.65 8.86
2010-09-30 14.36 $1.71 8.42
2010-06-30 13.83 $1.65 8.38
2010-03-31 18.34 $1.56 11.76
2009-12-31 17.45 $1.42 12.33
2009-09-30 18.75 $1.28 14.65
2009-06-30 18.89 $1.18 16.01
2009-03-31 18.68 $1.11 16.91
2008-12-31 20.63 $1.05 19.74
2008-09-30 18.40 $0.95 19.37
2008-06-30 21.36 $0.90 23.73
2008-03-31 20.78 $0.88 23.62
2007-12-31 18.56 $0.84 22.16
2007-09-30 16.48 $-0.27 0.00
2007-06-30 15.65 $-0.51 0.00
2007-03-31 15.46 $-0.58 0.00
2006-12-31 13.09 $-0.66 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $85.060B $24.689B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.345B 9.06
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.301B 19.14
Biohaven Pharmaceutical Holding (BHVN) United States $7.598B 0.00
Emergent Biosolutions (EBS) United States $2.503B 9.00
Arcus Biosciences (RCUS) United States $2.274B 0.00
Myovant Sciences (MYOV) United Kingdom $1.296B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.081B 0.00
Zymeworks (ZYME) Canada $0.538B 0.00
SQZ Biotechnologies (SQZ) United States $0.203B 0.00
Ambrx Biopharma (AMAM) United States $0.201B 0.00
Enzo Biochem (ENZ) United States $0.155B 20.00